309 related articles for article (PubMed ID: 22445709)
1. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan.
Komaba H; Moriwaki K; Goto S; Yamada S; Taniguchi M; Kakuta T; Kamae I; Fukagawa M
Am J Kidney Dis; 2012 Aug; 60(2):262-71. PubMed ID: 22445709
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States.
Boer R; Lalla AM; Belozeroff V
J Med Econ; 2012; 15(3):509-20. PubMed ID: 22313328
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA.
Ray JA; Borker R; Barber B; Valentine WJ; Belozeroff V; Palmer AJ
Value Health; 2008; 11(5):800-8. PubMed ID: 18494747
[TBL] [Abstract][Full Text] [Related]
6. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective.
Garside R; Pitt M; Anderson R; Mealing S; D'Souza R; Stein K
Nephrol Dial Transplant; 2007 May; 22(5):1428-36. PubMed ID: 17308322
[TBL] [Abstract][Full Text] [Related]
7. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries.
Iannazzo S; Carsi M; Chiroli S
Appl Health Econ Health Policy; 2012 Mar; 10(2):127-38. PubMed ID: 22268372
[TBL] [Abstract][Full Text] [Related]
8. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis.
Narayan R; Perkins RM; Berbano EP; Yuan CM; Neff RT; Sawyers ES; Yeo FE; Vidal-Trecan GM; Abbott KC
Am J Kidney Dis; 2007 Jun; 49(6):801-13. PubMed ID: 17533023
[TBL] [Abstract][Full Text] [Related]
9. Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.
Belozeroff V; Chertow GM; Graham CN; Dehmel B; Parfrey PS; Briggs AH
Value Health; 2015 Dec; 18(8):1079-87. PubMed ID: 26686794
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.
Eandi M; Pradelli L; Iannazzo S; Chiroli S; Pontoriero G
Pharmacoeconomics; 2010; 28(11):1041-54. PubMed ID: 20936886
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
[TBL] [Abstract][Full Text] [Related]
12. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
13. Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet.
Belozeroff V; Lee A; Tseng S; Chiroli S; Campbell JD
J Med Econ; 2013 Sep; 16(9):1154-62. PubMed ID: 23869940
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
16. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
[TBL] [Abstract][Full Text] [Related]
17. [Is Cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis?].
Arenas MD; Rebollo P; Alvarez-Ude F; Prieto L; Gil MT; Malek T; Moledous A; Núñez C
Nefrologia; 2008; 28(5):511-6. PubMed ID: 18816209
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.
Zitt E; Rix M; Ureña Torres P; Fouque D; Jacobson SH; Pétavy F; Dehmel B; Ryba M
Nephrol Dial Transplant; 2011 Jun; 26(6):1956-61. PubMed ID: 20947534
[TBL] [Abstract][Full Text] [Related]
19. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.
Tominaga Y; Matsuoka S; Uno N; Sato T
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S21-6. PubMed ID: 19032523
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial.
Liu L; Hong D; Ma K; Wu B; Lu X
BMJ Open; 2020 Aug; 10(8):e034123. PubMed ID: 32753447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]